Streetbeat News

Products Services

BCRX

BioCryst Pharmaceuticals has successfully completed negotiations with the Pan-Canadian Pharmaceutical Alliance for Orladeyo, a drug approved in Canada for preventing hereditary angioedema attacks in patients aged 12 and older.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:12 am

ACIU

AC Immune SA (NASDAQ:ACIU) has received a CHF 24.6 million milestone payment from Janssen Pharmaceuticals for its Alzheimer's immunotherapy candidate, JNJ-2056. This payment highlights the progress in the Phase 2b ReTain trial and strengthens AC Immune's financial position.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:11 am

LASE

Laser Photonics has received an order from Pearl Harbor Naval Shipyard for its DefenseTech laser cleaning tool, indicating a potential increase in demand for its products in the defense sector.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:11 am

VIGL

The FDA has lifted the partial clinical hold on Vigil Neuroscience's Phase 1 trial of VG-3927 after the company submitted a complete response. Full data from the trial is expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:09 am

PXLW

Universal Pictures has partnered with Pixelworks to integrate TrueCut Motion technology into its films, starting with 'The Wild Robot'. This technology enhances the cinematic experience by allowing filmmakers to fine-tune motion looks in post-production.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:09 am

CGEM

Cullinan Therapeutics (NASDAQ:CGEM) has received approval in Australia to begin a global Phase 1 trial for its SLE treatment, CLN-978. This novel therapy aims to provide a more effective treatment option for SLE, a condition affecting 430,000 people globally.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:07 am

RCKT

Rocket Pharmaceuticals has completed patient enrollment for its global Phase 2 clinical trial of RP-A501, aimed at treating Danon Disease in male patients. This marks a significant milestone in the development of this potential treatment.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:06 am

VERI

Veritone, Inc. (NASDAQ:VERI) will showcase its AI solutions at HR Tech 2024, demonstrating how they can reduce recruitment costs by 80%. The company will present its Veritone Hire suite, which includes programmatic job advertising, job distribution, and compliance solutions.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:06 am

ACRS

Aclaris Therapeutics has initiated a Phase 2a trial for ATI-2138, targeting moderate to severe atopic dermatitis. The trial will assess safety, tolerability, and efficacy over 12 weeks with 15 subjects in the US. Results are expected in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:04 am

DPRO

Draganfly Inc and Nightingale Security have secured a contract with a major oil and gas company to develop an automated UAS monitoring solution. This project aims to enhance operational efficiency and safety in the oil and gas sector using advanced UAV technology. The financial terms were not disclosed, and the project is currently in the testing phase.

Portfolio Pulse from Anusuya Lahiri

September 17, 2024 | 11:03 am